Mylan's shareholders just voted against its executive pay, which included a $100 million package for its chairman
Thomson Reuters
Shareholders also voted against a measure to approve the company's executive compensation. The shareholder campaign against Mylan's board picked up steam after Chairman Robert Coury's nearly $100 million pay package was disclosed earlier this year.
Coury made roughly $98 million in 2016, according to company filings, in a year in which the company faced criticism for the price of the emergency allergy device EpiPen and the stock fell almost 30%.
The generic pharmaceutical company came into the spotlight in August 2016 for raising the price of the EpiPen to $608.61 from $93.88 over the past decade. It caught the nation's attention because parents were refilling their kids' prescriptions, and some found that they were on the hook for hundreds of dollars for the device.
The company did not disclose the vote totals for the directors.
(Reporting by Toby Sterling, Writing by Michael Erman in New York; Editing by Chizu Nomiyama)
- I got a $40K raise using this 30-second strategy. It made me realize loud work, not hard work, always wins.
- A millennial manager went viral after her Gen Z assistant picked up a work call while at the hair salon: 'Go off queen'
- Qatar Airways' new CEO explains why it's sticking with the Airbus A380 as other airlines retire the costly superjumbo
- Kia India looks to expand sales, service network to 700 touchpoints by year-end
- Shapoorji Pallonji’s Afcons Infra files DRHP for ₹7,000 crore IPO
- Water crisis affects businesses across Bengaluru; Is there room for cautious optimism?
- BenQ Zowie EC2-CW review – Premium wireless mouse for gamers
- Banks' GNPAs set to improve further to 2.1 pc by FY25: Care Ratings